A Phase II Evaluation of Pazopanib (NSC 737754, IND 75648) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus.
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Uterine cancer
- Focus Adverse reactions; Therapeutic Use
- 06 May 2016 Status changed from active, no longer recruiting to completed.
- 01 Mar 2014 Interim results (n=22) published in the Gynecologic Oncology.
- 11 Mar 2013 Planned End Date changed from 1 Feb 2014 to 1 May 2016 as reported by ClinicalTrials.gov.